 |
|
Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
Christie M. Ballantyne, MD;
Ron C. Hoogeveen, PhD;
Heejung Bang, PhD;
Josef Coresh, MD, PhD;
Aaron R. Folsom, MD, MPH;
Lloyd E. Chambless, PhD;
Merle Myerson, MD, EdD;
Kenneth K. Wu, MD, PhD;
A. Richey Sharrett, MD, DrPH;
Eric Boerwinkle, PhD
Arch Intern Med. 2005;165:2479-2484.
Background Measurement of inflammatory markers has been reported to identify individuals at increased risk for ischemic stroke. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme secreted by macrophages. We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke.
Methods A proportional hazards model was used in a prospective case-cohort study of 12 762 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study who were observed for about 6 years.
Results Mean Lp-PLA2 and CRP levels adjusted for sex, race, and age were higher in the 194 stroke cases than the 766 noncases, whereas low-density lipoprotein cholesterol (LDL-C) level was not significantly different. Both Lp-PLA2 and CRP levels were associated with ischemic stroke after adjustment for age, sex, and race: hazard ratios were 2.23 for the highest vs the lowest tertile of Lp-PLA2 and 2.70 for CRP level higher than 3 vs lower than 1 mg/L. In a model that included smoking, systolic hypertension, lipid levels, and diabetes, Lp-PLA2 and CRP levels in the highest category were associated with hazard ratios of 1.91 (95% confidence interval, 1.15-3.18; P = .01) and 1.87 (95% confidence interval, 1.13-3.10; P = .02), respectively. Individuals with high levels of both CRP and Lp-PLA2 were at the highest risk after adjusting for traditional risk factors compared with individuals with low levels of both, whereas others were at intermediate risk.
Conclusion Levels of Lp-PLA2 and CRP may be complementary beyond traditional risk factors in identifying middle-aged individuals at increased risk for ischemic stroke.
Author Affiliations: Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Tex (Drs Ballantyne and Hoogeveen); Department of Biostatistics, School of Public Health, The University of North Carolina at Chapel Hill (Drs Bang and Chambless); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md (Drs Coresh and Sharrett); Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis (Dr Folsom); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (Dr Myerson); and Vascular Biology Research Center, Department of Internal Medicine (Dr Wu), and the Human Genetics Center, School of Public Health (Dr Boerwinkle), The University of Texas Health Science Center at Houston.
RELATED ARTICLES
When Is a New Prediction Marker Useful?: A Consideration of Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Stroke Risk
Philip Greenland and Patrick G. O’Malley
Arch Intern Med. 2005;165(21):2454-2456.
EXTRACT
| FULL TEXT
C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study
Peter W. F. Wilson, Byung-Ho Nam, Michael Pencina, Ralph B. D’Agostino, Sr, Emelia J. Benjamin, and Christopher J. O’Donnell
Arch Intern Med. 2005;165(21):2473-2478.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial
Robins et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1172-1178.
ABSTRACT
| FULL TEXT
Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques
Mannheim et al.
Stroke 2008;39:1448-1455.
ABSTRACT
| FULL TEXT
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Mohler et al.
J Am Coll Cardiol 2008;51:1632-1641.
ABSTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women
Wassertheil-Smoller et al.
Hypertension 2008;51:1115-1122.
ABSTRACT
| FULL TEXT
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
Daniels et al.
J Am Coll Cardiol 2008;51:913-919.
ABSTRACT
| FULL TEXT
Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms
Air and Kissela
Diabetes Care 2007;30:3131-3140.
FULL TEXT
Assessing inflammatory status in cardiovascular disease
Tousoulis et al.
Heart 2007;93:1001-1007.
FULL TEXT
Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)
Winkler et al.
Clin. Chem. 2007;53:1440-1447.
ABSTRACT
| FULL TEXT
Cardiovascular Biomarkers: Added Value With an Integrated Approach?
Koenig
Circulation 2007;116:3-5.
FULL TEXT
Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans
Lavi et al.
Circulation 2007;115:2715-2721.
ABSTRACT
| FULL TEXT
Letter by Ridker and Everett Regarding Article, "The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?"
Ridker and Everett
Circulation 2007;115:e475-e475.
FULL TEXT
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Koenig and Khuseyinova
Arterioscler. Thromb. Vasc. Bio. 2007;27:15-26.
ABSTRACT
| FULL TEXT
The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women
Everett et al.
J Am Coll Cardiol 2006;48:2235-2242.
ABSTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community
Gerber et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2517-2522.
ABSTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis
Kolodgie et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2523-2529.
ABSTRACT
| FULL TEXT
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Elkind et al.
Arch Intern Med 2006;166:2073-2080.
ABSTRACT
| FULL TEXT
Lp-PLA2: A New Kid on the Block
Zalewski et al.
Clin. Chem. 2006;52:1645-1650.
ABSTRACT
| FULL TEXT
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT
Lipoprotein-Associated Phospholipase A2 and Cardiovascular Risk: State of the Evidence and Future Directions
Iribarren
Arterioscler. Thromb. Vasc. Bio. 2006;26:5-6.
FULL TEXT
When Is a New Prediction Marker Useful?: A Consideration of Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Stroke Risk
Greenland and O'Malley
Arch Intern Med 2005;165:2454-2456.
FULL TEXT
|
